

# Annalisa Chiappella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3821025/publications.pdf>

Version: 2024-02-01

180  
papers

3,885  
citations

117453

34  
h-index

143772

57  
g-index

184  
all docs

184  
docs citations

184  
times ranked

4905  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. <i>Blood</i> , 2012, 119, 2066-2073.	0.6	217
2	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	0.8	190
3	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 730-737.	5.1	164
4	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
5	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
6	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015, 6, 6921.	5.8	111
7	Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. <i>Annals of Oncology</i> , 2013, 24, 2119-2123.	0.6	107
8	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , the, 2017, 4, e15-e23.	2.2	106
9	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , 2009, 23, 1118-1126.	3.3	104
10	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	5.1	100
11	Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. <i>Radiologia Medica</i> , 2008, 113, 578-590.	4.7	91
12	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018, 29, 2363-2370.	0.6	89
13	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
14	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013, 122, 3759-3766.	0.6	82
15	Nonpegylated liposomal doxorubicin (Myocetâ„¸) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO18 trial. <i>Annals of Oncology</i> , 2010, 21, 1492-1499.	0.6	81
16	A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015, 26, 1667-1677.	0.6	80
17	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	0.6	74
18	Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. <i>Blood</i> , 2017, 129, 2328-2330.	0.6	72

#	ARTICLE	IF	CITATIONS
19	Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 381-385.	1.4	70
20	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009, 94, 1250-1258.	1.7	65
21	Iron Overload in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Quantification of Iron Burden by a Superconducting Quantum Interference Device (SQUID) and Therapeutic Effectiveness of Phlebotomy. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 115-122.	2.0	57
22	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.	3.3	56
23	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014, 99, 489-496.	1.7	55
24	Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 3351-3359.	0.8	54
25	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013, 98, 1732-1738.	1.7	54
26	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019, 185, 940-944.	1.2	49
27	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
28	Gains of <i>MYC</i> locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2011, 155, 274-277.	1.2	47
29	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
30	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
31	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , 2015, 29, 1390-1401.	3.3	42
32	ALK signaling and target therapy in anaplastic large cell lymphoma. <i>Frontiers in Oncology</i> , 2012, 2, 41.	1.3	39
33	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2013, 54, 699-707.	0.6	37
34	Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 311-316.	0.4	35
35	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 3606-3610.	2.5	35
36	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 38.	6.9	34

#	ARTICLE	IF	CITATIONS
37	CD38, BCL-2, PD-1, and PD-L1 expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. American Journal of Hematology, 2017, 92, E1-E2.	2.0	33
38	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer Journal, 2018, 8, 108.	2.8	32
39	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 42-49.	0.4	31
40	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood, 2011, 117, 2405-2413.	0.6	30
41	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leukemia and Lymphoma, 2016, 57, 1823-1830.	0.6	30
42	Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. Expert Review of Hematology, 2017, 10, 289-297.	1.0	30
43	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematological Oncology, 2011, 29, 38-41.	0.8	29
44	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematology, 2021, 8, e34-e44.	2.2	29
45	Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. Journal of Cancer Research and Clinical Oncology, 2010, 136, 611-615.	1.2	28
46	Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer, 2010, 116, 4573-4579.	2.0	28
47	Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. Blood, 2016, 128, 622-622.	0.6	28
48	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. Thrombosis and Haemostasis, 2017, 117, 1615-1621.	1.8	27
49	Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. Expert Review of Hematology, 2017, 10, 697-705.	1.0	26
50	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematology, 2020, 7, e649-e659.	2.2	24
51	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood Cancer Journal, 2018, 8, 63.	2.8	22
52	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Advances, 2021, 5, 640-648.	2.5	22
53	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood, 2022, 140, 1907-1916.	0.6	22
54	Prognostic Role of Pre-Radiation Therapy 18F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1239-1243.	0.4	20

#	ARTICLE	IF	CITATIONS
55	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012, 23, 729-735.	0.6	19
56	Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IP1 2 <sup>â€³</sup> ) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012, 120, 688-688.	0.6	19
57	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. <i>British Journal of Haematology</i> , 2022, 196, 1184-1193.	1.2	19
58	&lt;i>&gt;CDKN2A&lt;/i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). <i>Haematologica</i> , 2021, 106, 2918-2926.	1.7	18
59	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	1.7	17
60	PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis Research</i> , 2016, 140, S177.	0.8	16
61	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 628-634.	2.0	16
62	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	1.7	15
63	High-grade B-cell lymphoma: how to diagnose and treat. <i>Expert Review of Hematology</i> , 2019, 12, 497-506.	1.0	15
64	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 2398-2404.	0.6	14
65	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503.	1.2	12
66	Lenalidomide in Diffuse Large B-Cell Lymphomas. <i>Advances in Hematology</i> , 2012, 2012, 1-5.	0.6	12
67	Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. <i>Blood Cancer Journal</i> , 2014, 4, e249-e249.	2.8	11
68	State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1147-1162.	0.9	11
69	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	0.6	11
70	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	1.7	11
71	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 330-334.	1.2	10
72	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	1.9	10

#	ARTICLE	IF	CITATIONS
73	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 398-398.	0.6	10
74	Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). <i>Blood</i> , 2007, 110, 1278-1278.	0.6	10
75	Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP. <i>Blood</i> , 2009, 114, 99-99.	0.6	10
76	The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP. <i>Blood</i> , 2014, 124, 2964-2964.	0.6	10
77	Are We Ready to Treat Diffuse Large B-Cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019, 3, e284.	1.2	9
78	A three-gene signature based on MYC, BCL-2 and NFKB1A improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.	1.7	8
79	Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. <i>Expert Review of Hematology</i> , 2019, 12, 787-796.	1.0	7
80	Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2018, 132, 401-401.	0.6	7
81	Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4204-4204.	0.6	7
82	Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2021, 62, 3474-3483.	0.6	7
83	The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21. <i>Blood</i> , 2008, 112, 480-480.	0.6	6
84	Update in Indolent Non-Hodgkin Lymphoma (NHL): Paradigm for Waldenström's Macroglobulinemia (WM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 149-151.	0.2	5
85	Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study. <i>Blood</i> , 2006, 108, 208-208.	0.6	5
86	Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. <i>Annals of Hematology</i> , 2018, 97, 1619-1626.	0.8	4
87	Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era. <i>Lancet Oncology</i> , The, 2018, 19, 162-163.	5.1	4
88	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1a/2 study. <i>British Journal of Haematology</i> , 2018, 182, 453-456.	1.2	4
89	Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 449-449.	0.6	4
90	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4

#	ARTICLE	IF	CITATIONS
91	Radioimmunotherapy (RIT) with 90Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.. Blood, 2007, 110, 4478-4478.	0.6	4
92	The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy.. Blood, 2010, 116, 2819-2819.	0.6	4
93	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). Blood, 2011, 118, 777-777.	0.6	4
94	Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 903-903.	0.6	4
95	Comparison Of R-CHOP14 and R-CHOEP14 As First Line Treatment In Young Patients With High-Risk (aalPI) Tj ETQq1 1 0.784314 rgB... Trials Conducted By The Fondazione Italiana Linfomi (FIL) and The German High-Grade Lymphoma Study Group (DSHNHL). Blood, 2013, 122, 4341-4341.	0.6	4
96	The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. Blood Advances, 2022, 6, 4634-4644.	2.5	4
97	A Prospective, Observational Study Evaluating Early Subclinical Cardiotoxicity with Global Longitudinal Strain Imaging in Lymphoma Patients Treated with Chemotherapy +/- Mediastinal Radiation Therapy: The CARDIOCARE Project. International Journal of Radiation Oncology Biology Physics, 2018, 102, S88.	0.4	3
98	OUTCOMES IN FIRST RELAPSED&#x2013;REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE&#x2013;FIRST STUDY. Hematological Oncology, 2019, 37, 46-47.	0.8	3
99	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. Hematological Oncology, 2019, 37, 244-245.	0.8	3
100	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. Bone Marrow Transplantation, 2021, 56, 2606-2609.	1.3	3
101	ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S376-S377.	0.2	3
102	The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma. Lancet Haematology,the, 2021, 8, e617-e619.	2.2	3
103	Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi. Blood, 2018, 132, 2902-2902.	0.6	3
104	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. Blood, 2013, 122, 850-850.	0.6	3
105	Activated B-Cell (ABC) Profile Does Not Have An Inferior Outcome Compared to Germinal Center B-Cell (GCB) Profile Determined by Immunohistochemistry Tissue Microarray in Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and Dose- Dense and High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT).. Blood, 2008, 112, 1139-1139.	0.6	3
106	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. Blood, 2021, 138, 134-134.	0.6	3
107	Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem. Blood, 2021, 138, 3867-3867.	0.6	3
108	XVI. CNS prophylaxis in aggressive lymphomas: for whom and how. Hematological Oncology, 2013, 31, 89-91.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab. <i>Journal of Chemotherapy</i> , 2016, 28, 435-440.	0.7	2
110	CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL). <i>Annals of Oncology</i> , 2018, 29, iii9.	0.6	2
111	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 41-42.	0.6	2
112	Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III-IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.. <i>Blood</i> , 2006, 108, 329-329.	0.6	2
113	The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi.. <i>Blood</i> , 2009, 114, 3758-3758.	0.6	2
114	Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.. <i>Blood</i> , 2010, 116, 2821-2821.	0.6	2
115	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 3047-3047.	0.6	2
116	Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2014, 124, 1755-1755.	0.6	2
117	The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 2735-2735.	0.6	2
118	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016, 128, 3033-3033.	0.6	2
119	Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components. <i>Blood</i> , 2016, 128, 4098-4098.	0.6	2
120	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016, 128, 472-472.	0.6	2
121	Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7538-7538.	0.8	2
122	Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.. <i>Blood</i> , 2005, 106, 676-676.	0.6	2
123	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3049-3049.	0.6	2
124	The risk of CNS involvement in aggressive lymphomas in the rituximab era. <i>Expert Review of Hematology</i> , 2013, 6, 643-652.	1.0	1
125	A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). <i>Annals of Oncology</i> , 2016, 27, vi316.	0.6	1
126	Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e558.	5.1	1



#	ARTICLE	IF	CITATIONS
127	Histological transformation and secondary malignancies in follicular lymphoma. <i>Lancet Haematology</i> , 2018, 5, e496-e497.	2.2	1
128	Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma. <i>Lancet Oncology</i> , 2018, 19, 1144-1146.	5.1	1
129	Monoclonal antibody-drug conjugates in B-cell lymphomas. <i>Lancet Haematology</i> , 2019, 6, e232-e233.	2.2	1
130	P14.85 Brain metastasis from Hodgkin's Lymphoma: case report and literature review. <i>Neuro-Oncology</i> , 2019, 21, iii87-iii88.	0.6	1
131	Selective inhibitors of nuclear export in aggressive B-cell lymphomas. <i>Lancet Haematology</i> , 2020, 7, e500-e501.	2.2	1
132	Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. <i>Blood</i> , 2018, 132, 676-676.	0.6	1
133	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
134	Mid-Treatment Evaluation of 18-FDG-Positron Emission Tomography/Computed Tomography (PET) as Predictive Value of Response Assessment in Aggressive Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2007, 110, 2333-2333.	0.6	1
135	Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized III Trial. <i>Blood</i> , 2008, 112, 834-834.	0.6	1
136	Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial. <i>Blood</i> , 2009, 114, 1706-1706.	0.6	1
137	Response Assessment After Induction Therapy in Diffuse Large B Cell Lymphoma (DLBCL): Role of Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) in Comparison with Computed Tomography (CT). <i>Blood</i> , 2009, 114, 4995-4995.	0.6	1
138	Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL). <i>Blood</i> , 2010, 116, 3965-3965.	0.6	1
139	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014, 124, 3074-3074.	0.6	1
140	GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes. <i>Blood</i> , 2015, 126, 3889-3889.	0.6	1
141	A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 4199-4199.	0.6	1
142	Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST). <i>Journal of Clinical Oncology</i> , 2018, 36, 7548-7548.	0.8	1
143	Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 7562-7562.	0.8	1
144	Pre-Autologous Stem Cell Transplantation (ASCT) Treatment with Rituximab Does Not Impair Stem Cell Harvest and Engraftment in Untreated Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis. <i>Blood</i> , 2005, 106, 2738-2738.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2007, 110, 1899-1899.	0.6	1
146	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. Blood, 2010, 116, 1784-1784.	0.6	1
147	Outcome of Elderly Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Prospectively Identified by Comprehensive Geriatric Assessment (CGA). Results From a Study of the Intergruppo Italiano Linfomi (IIL). Blood, 2010, 116, 1771-1771.	0.6	1
148	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. Blood, 2015, 126, 3937-3937.	0.6	1
149	Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). Blood, 2015, 126, 3934-3934.	0.6	1
150	Checkpoint Inhibition before Axicabtagene Ciloleuce Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting. Blood, 2020, 136, 12-13.	0.6	1
151	Changing treatment paradigms in lymphoma: new targets and new drugs. Memo - Magazine of European Medical Oncology, 2015, 8, 184-188.	0.3	0
152	Poster: ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S244.	0.2	0
153	Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study.. Blood, 2004, 104, 1321-1321.	0.6	0
154	Radioimmunotherapy (RIT) with 90y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens. Blood, 2008, 112, 5014-5014.	0.6	0
155	Validation of Mantle Cell International Prognostic Index (MIPI) in Mantle Cell Lymphoma (MCL) in a Retrospective Single Institution Series. Blood, 2008, 112, 2828-2828.	0.6	0
156	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. Blood, 2008, 112, 478-478.	0.6	0
157	Quantification by Superconducting Quantum Interference Device (SQUID) of Iron Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2008, 112, 2134-2134.	0.6	0
158	Mid-Treatment 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Does Not Impact the Outcome in Patients with Aggressive Non Hodgkin Lymphoma (NHL). Blood, 2008, 112, 5295-5295.	0.6	0
159	Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.. Blood, 2009, 114, 2928-2928.	0.6	0
160	Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP.. Blood, 2009, 114, 3957-3957.	0.6	0
161	Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).. Blood, 2009, 114, 2316-2316.	0.6	0
162	The Host Genetic Background of DNA Repair Mechanisms Represents An Independent Predictor of Progression and Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.. Blood, 2009, 114, 442-442.	0.6	0

#	ARTICLE	IF	CITATIONS
163	The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study. <i>Blood</i> , 2010, 116, 992-992.	0.6	0
164	Prospective, Multicenter Phase II Pilot Trial to Evaluate Efficacy and Safety of Lenalidomide Plus Rituximab-CHOP21 (LR-CHOP21) for Elderly Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis of the Intergruppo Italiano Linfomi (IIL) REAL07 Study. <i>Blood</i> , 2010, 116, 2871-2871.	0.6	0
165	Radioimmunotherapy (RIT) with <sup>90</sup> yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2011, 118, 3107-3107.	0.6	0
166	Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI $\geq 3$ ) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis. <i>Blood</i> , 2011, 118, 1606-1606.	0.6	0
167	Rituximab Plus Dose Intense Rapid-Cycling Chemotherapy with Intrathecal CNS Prophylaxis in Patients with Burkitt Lymphoma (BL) and Intermediate Unclassifiable Diffuse Large B-Cell Lymphoma/BL: Single Institution Experience. <i>Blood</i> , 2011, 118, 1631-1631.	0.6	0
168	R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2012, 120, 1615-1615.	0.6	0
169	Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 5088-5088.	0.6	0
170	Impact Of Bone Marrow Involvement On Outcome Of Young Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Treated In The Phase III Randomized Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy Followed By Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Or Standard Rituximab Dose Dense Chemotherapy: A Study of The Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2013, 122, 4340-4340.	0.6	0
171	Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study. <i>Blood</i> , 2013, 122, 5119-5119.	0.6	0
172	The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 5041-5041.	0.6	0
173	De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC). <i>Blood</i> , 2015, 126, 2650-2650.	0.6	0
174	Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohistochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP. <i>Blood</i> , 2016, 128, 5305-5305.	0.6	0
175	Intensified therapy in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 12548-12549.	0.8	0
176	Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. <i>Blood</i> , 2018, 132, 4115-4115.	0.6	0
177	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HROoL) Analysis of the International Robust Study. <i>Blood</i> , 2019, 134, 3475-3475.	0.6	0
178	The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 2025-2025.	0.6	0
179	Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy. <i>Blood</i> , 2021, 138, 3877-3877.	0.6	0
180	A Novel Method for Molecular Enumeration of Circulating Tisa-Cel and Axi-Cel in Lymphoma Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	0